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Background: Fingolimod is an innovative drug with a significant budget impact in the treatment of MS in Spain.
The aim of this study was to calculate the direct cost comparison of glatiramer acetate and fingolimod for the
treatment of patients with relapsing-remitting multiple sclerosis (RRMS) in Spain.
Methods: A cost analysis model was developed to compare glatiramer acetate and fingolimod, based on a 1-year
time horizon. In addition to the pharmacological costs, resource use was estimated for glatiramer acetate (1 hour of
training with nursing staff in self-injection techniques for subcutaneous administration) and fingolimod (vaccination
for varicella-zoster virus in 5% of patients, 3 complete blood counts per year, 3 ophthalmology visits for prevention
of macular edema, 3 transaminase tests to monitor liver function, and cardiovascular monitoring consisting of 1
ECG before the first fingolimod dose and at 6 hours; 1 day outpatients-hospital visit for cardiological monitoring
during 6 hours on the day of the first fingolimod dose, with follow-up of blood pressure and heart rate every hour).
The pharmacological costs were calculated based on the ex-factory price of the drugs evaluated, using the doses
recommended in the respective Summary of Products Characteristics (SmPC). Total invoicing volume was
discounted by 7.5%, as laid down in Spanish Royal Decree 8/2010. Unit costs were obtained from the e-Salud
database and the drug catalog. Costs in the model are expressed in €2012.
Results: The cost of annual treatment was €9,439.42 for glatiramer acetate and €19,602.18 for fingolimod, yielding a
cost difference of €10,162.76. Assuming a fixed budget of €100,000.00, approximately 10 patients could be treated
with glatiramer acetate, compared to 5 with fingolimod.
Conclusions: Fingolimod therapy requires twice the investment as glatiramer acetate.
Keywords: Relapsing-remitting multiple sclerosis (RRMS), Cost analysis model, Economic evaluation, Glatiramer
acetate, FingolimodBackground
Multiple sclerosis (MS) is a chronic, autoimmune, neu-
rodegenerative disease affecting the central nervous sys-
tem, which is associated with an irreversible progressive
disability that causes great concern for the patient. It
most affects young adults [1]. The most common clinical
form is relapsing-remitting multiple sclerosis (RRMS)
which can represent up to 65% of all patients with MS
[2]. In Spain, the prevalence reported is from 50–70* Correspondence: rainel.sanchez@tevaes.com
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reproduction in any medium, provided the origcases per 100,000 inhabitants [3,4]. Unfortunately, it is
not currently possible to cure MS, the treatments avail-
able in the therapeutic armamentarium up to now have
centered their action on the anti-inflammatory and
disease course-modifying effect, and the purpose of
treatment is to prevent recurrence of relapses and accu-
mulation of disability. A few disease-modifying therapies
(DMTs) including Interferon beta-1a, beta-1b and
glatiramer acetate have been approved for patients with
RRMS to delay disease progression and reduce the inci-
dence of relapses [5]. Fingolimod, the first DMT oral
formulation, was recently approved by EMA. Therefore,
treatment of RRMS has changed with the introductionger. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
Table 1 Unit costs
Units Cost (€ 2012)
Pharmacological cost
GA (Copaxone®), 20 mg/mL,
28 1-mL prefilled syringes
Per presentation €781.25




Cost per hour of nursing care 1 hour €19.08
Ophthalmology visit Per visit €37.88
Day hospital visit Per visit €137.59
Vaccines
Varicella vaccine 1 vaccine €43.50
Tests
Electrocardiogram Per test €20.34
Complete blood count Per test €6.93
Transaminases Per test €4.93
GA: glatiramer acetate.
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nificant impact on the budget dedicated to treatment of
MS. At this time, it has the highest treatment/cost/pa-
tient/year in Spain [6]. Both glatiramer acetate and
fingolimod reduce progression and relapses among pa-
tients with RRMS. Compared to glatiramer acetate,
fingolimod-treated patients were at increased risk of
some unintended treatment effects [7,8].
The current financial scenario reinforces the payers’
needs (National Health System, NHS) of review with
care the rational use of treatments. According to the
spending rule approved by law in 2012 [9] CCAA can-
not exceed the reference rate of GDP, representing
huge pressure to reduce immediately its budget deficit
and direct drug costs. Moreover, the Government of
Spain has cut back 2013 Ministry of Health’s budget by
22.6% [10].
This study was carried out with the purpose of evalu-
ating the economic feasibility of management of treat-




Cost of infection management €0.00
Cost of prevention of macular edema €0.00
Cost of liver function monitoring €0.00
Cost of cardiovascular monitoring €0.00
TOTAL COST PER PATIENT/YEAR €9,439.42
GA, Glatiramer acetate.using a model of direct cost comparison from the
Spanish payers’ perspective.Methods
Study design
For the purpose of conducting this study, a cost com-
parison model was developed and implemented in an
application of the Microsoft Excel 2003 software includ-
ing as therapeutic alternatives glatiramer acetate (GA;
Copaxone®, Teva Pharmaceutical Ltd) and fingolimod
(Gilenya®, Novartis Europharm Ltd).Perspective and time horizon
The perspective of the analysis was that of the payer
(NHS, Autonomous Community or hospitals) and the
time horizon was set to 1 year, so this is the usual period
used by the payer in planning of its budgets.Resources
Only resources related to direct health costs that are fi-
nanced by the health authorities were considered: Drugs;
Treatment administration: only for glatiramer acetate
[8], for all patients starting treatment was considered ne-
cessary to have a one hour session of training by qualified
nursing staff, equivalent to a nursing visit; Prevention of
infections: only for fingolimod, as recommended in its
SmPC [8], was considered vaccination for varicella-zoster
virus in 5% of patients and 3 complete blood counts per
year; Monitoring of liver function: only for fingolimod, as
recommended in its SmPC [8], were considered 3 trans-
aminase tests per year (SGOT, SGPT, GGT); Prevention of
macular edema: only for fingolimod, as recommended in
its SmPC [8], were considered 3 ophthalmology visits per
year; Cardiovascular monitoring: only for fingolimod, as
recommended in its SmPC, was considered an ECG before
the first fingolimod dose and at 6 hours. 1 day outpatients-
hospital visit for cardiological monitoring during 6 hours
on the day of the first fingolimod dose, with follow-up of









Figure 1 Patients treated with fixed budget.
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The pharmacological costs were calculated based on the
ex-factory price of the two drugs evaluated, according to
the doses and conditions of use recommended in the re-
spective SmPC. The cost of medical visits is determined
as follows. First, the cost of the initial neurologist’s visit
is considered. This is based on the yearly cost of patient
starting treatment. Then, all successive neurologists’
visits are estimated using the unit cost a typical follow-
up visit.
Unit costs of the drugs used in the model were
obtained from the e-Salud database [11] and the drugFigure 2 Budget according to number of patients treated.catalog [12]. All costs in the model are expressed in
€2012. A 7.5% discount was applied for these prices as
laid down in Spanish Royal Decree 8/2010 (of May 20,
when extraordinary measures to reduce the public deficit
were adopted [13] (Table 1).
Sensitivity analyses
To reduce the uncertainty of the model assumptions, uni-
variate sensitivity analyses were performed by decreasing
values for key parameters in the model. Analyzed parame-
ters included 10% and 20% discount rate in glatiramer
acetate or 10% discount in Fingolimod list price.
Table 3 Results of sensitivity analyses
GA Fingolimod GA-Fingolimod
Base Case €9,439.42 €19,602.18 €-10,162.76
10% rebate in GA & no rebate in Fingolimod list Price €8,478.30 €19,602.18 €-11,123.80
20% rebate in GA & no rebate in Fingolimod list Price €7,536.27 €19,602.18 €-12,065.91
10% rebate in Fingolimod & no rebate in GA list Price €9,439.42 €17,672.90 €-8,233.48
GA, Glatiramer acetate.
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The cost of treatment in the first year was €9,439.42 for
glatiramer acetate and €19,602.18 for fingolimod, yield-
ing a cost difference of €10,162.76 (Table 2).
The ratio of the cost of treatment with fingolimod was
2.1 times the cost of glatiramer acetate, i.e., assuming a
fixed budget of €5,000,000.00; approximately 530 pa-
tients could be treated with glatiramer acetate and only
255 with fingolimod (Figure 1).
The cost to treat 1000 patients with glatiramer acetate
is €9,439,420, whereas if they were treated with
fingolimod the cost would be €19,602,182 (Figure 2). In
Table 3 we presented the data from the sensitivity
analyses.
Discussion
Healthcare decision-making is complex and involves a
wide range of factors. For the payer, Spanish NHS, it is
very relevant to use a rational criterion when allocating
resources, which is based on clinical evidence, efficiency
and budget impact of the different therapeutic options
available for the management of a given disease [14,15].
In the case of MS, the availability of several drugs for its
treatment, each with its particularities and specific pro-
file, makes choosing the most appropriate treatment not
easy for physicians, patients, or the payer.
In Spain, MS treatment drugs are dispensed at the
hospital pharmacy. Pharmacological direct costs of man-
agement of this disabling disease accounts for 52% of all
resources required for its management and directly im-
pacts on the cost of each hospital [16]. The average
budget impact for the cohort of patients with RRMS
under treatment in Spain, considering all the options in-
dicated for first-line treatment, represents an investment
of €260 million annually, with an average cost per pa-
tient of €11,540 per year [17]. The use of the DMT in
real clinical practice setting has been a topic of substan-
tial debate for payers at hospital and CCAA level. In this
context, treatment with glatiramer acetate represents a
saving of 15.7% over total expenditure. The first oral
treatment for this disease, fingolimod, has recently been
marketed. This drug is the most expensive one available
on the Spanish market, which has led to a substantial in-
cremental cost in the budget dedicated to treatment of
MS by the NHS [6].This study, through an economic model of cost com-
parison from the perspective of the NHS, provides data
on two therapeutic alternatives. The use of glatiramer
acetate is a sustainable alternative within the current
policy of containment of pharmacological expenditure,
without sacrificing efficacy and safety in patients with
MS. These results are not new; there are previous
studies that have already shown that treatment with
glatiramer acetate represents a cost saving of between 5
to 14% as compared to other treatments for MS [18,19].
In Germany, a cost minimization analysis showed that,
compared to fingolimod, treatment of MS with inter-
feron beta-1b leads to substantial cost savings from the
perspective of society and payer [20]. A Canadian study
showed that despite fingolimod having a greater reduc-
tion in the annual relapse rate, it has the same net health
benefit as treatment with interferon beta-1b [21]. This
point should be taken into account together with the
greater cost of treatment with fingolimod.
We want to remark that treatment decision it is not
only based in cost, which at this time is a key parameter
to take into consideration, being particularly important
when it is possible to use both treatments according to
the patient performance and disease status. Based on
costs, it is necessary to point out glatiramer acetate is
the best option only in patients with similar health ef-
fects, but it could not be the best option in patients with
lower health effects. Physicians will always take the treat-
ment decisions taking into consideration the best
benefit- risk ratio for the patient.
This study has as a limitation: It has been made from
the perspective of the NHS. Therefore, only direct
healthcare costs have been taken into account and it did
not include the indirect costs related to loss of product-
ivity of patients or caregivers which can represent an im-
portant percentage of total cost [22]. In this regard,
further studies are needed that can provide differential
information on the indirect costs between both thera-
peutic alternatives.
Conclusions
Our study provides relevant information for decision
making from the perspective of the NHS. In conclusion,
treatment of RRMS with fingolimod has twice the impact
on the budget than glatiramer acetate. Consequently,
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tive that facilitates sustainability of a universal and com-
prehensive healthcare system with public funds.
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